$1.10
2.65%
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US00444T1007
Symbol
TLPH

AcelRx Pharmaceuticals, Inc. Stock price

$1.10
-0.21 16.03% 1M
+0.66 150.00% 6M
+0.58 109.88% YTD
+0.60 117.82% 1Y
-0.97 46.86% 3Y
-23.10 95.45% 5Y
-75.50 98.56% 10Y
-89.90 98.79% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.03 2.65%
ISIN
US00444T1007
Symbol
TLPH
Industry

Key metrics

Basic
Market capitalization
$51.3m
Enterprise Value
$30.0m
Net debt
positive
Cash
$21.3m
Shares outstanding
45.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1,709.0 | 1,827.8
EV/Sales
999.4 | 1,068.8
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
43.9%
Return on Equity
-162.5%
ROCE
-47.3%
ROIC
37.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$30.0k | $28.1k
EBITDA
$1.1b | -
EBIT
$-13.0m | $-13.8m
Net Income
$-12.4m | $-16.3m
Free Cash Flow
$-1.5b
Growth (TTM | estimate)
Revenue
-89.3% | -
EBITDA
8,938.0% | -
EBIT
-5.9% | 9.4%
Net Income
-5.9% | -25.2%
Free Cash Flow
-10,295.9%
Margin (TTM | estimate)
Gross
10,905,714.3%
EBITDA
3,882,389.3% | -
EBIT
-46,539.3%
Net
-44,242.9% | -58,023.6%
Free Cash Flow
-5,179,385.7%
More
EPS
$-0.3
FCF per Share
$-31.8
Short interest
4.4%
Employees
13
Rev per Employee
$0.0
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.03 0.03
89% 89%
100%
- Direct Costs 1,392 1,392
-
4,641,333%
3,054 3,054
-
10,178,667%
- Selling and Administrative Expenses 7.26 7.26
6% 6%
24,200%
- Research and Development Expense 5.80 5.80
1% 1%
19,333%
1,087 1,087
8,938% 8,938%
3,623,567%
- Depreciation and Amortization 1,100 1,100
-
3,667,000%
EBIT (Operating Income) EBIT -13 -13
6% 6%
-43,437%
Net Profit -12 -12
6% 6%
-41,300%

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AcelRx Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 2 months ago
Talphera, Inc. ( TLPH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - CEO & Director Shakil Aslam - Chief Medical Officer Conference Call Participants Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Welcome to the Talphera Third Quarter 2025 Financial Results Conference Call. This ca...
Neutral
PRNewsWire
about 2 months ago
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected i...
Neutral
PRNewsWire
about 2 months ago
SAN MATEO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast an...
More AcelRx Pharmaceuticals, Inc. News

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 13
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today